Perspective Therapeutics doses first patient in new VMT-α-NET Phase 1/2a cohort

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX

0.00
  • Perspective Therapeutics dosed the first patients in new cohorts of two ongoing Phase 1/2a radiopharmaceutical studies, expanding development programs in neuroendocrine tumors and other solid tumors.
  • For its SSTR2-targeting candidate [212Pb]VMT-α-NET, the newly opened cohort tests a revised dosing schedule intended to shape response timing while aiming to maintain tolerability at the same overall treatment exposure.
  • For its FAP-α-targeting candidate [212Pb]PSV359, the next cohort moved forward following a safety review, keeping the trial focused on establishing an acceptable safety profile while looking for early signs of anti-tumor activity.
  • Results have already been presented from an interim analysis of the VMT-α-NET study, while additional efficacy readouts from later patients are pending.
  • Further updates are slated for medical conference presentations during 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180630PRIMZONEFULLFEED9721870) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.